Three-Arm Randomized Phase III Trial: Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy

Hoopfer, Donna; Holloway, Caroline L.; Gabos, Zsolt; Alidrisi, Maha; Chafe, Susan; Krause, Barbara; Lees, Alan; Mehta, Nirmal; Tankel, Keith; Strickland, Faith M.; Hanson, John; King, Charlotte; Ghosh, Sunita; Severin, Diane

doi:10.1016/j.clbc.2014.12.006

Cited by 62 publications

(62 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moist desquamation often begins as small patches in skin folds and can progress to involve larger, confluent areas of irradiated skin. These symptoms are most pronounced in the axilla and inframammary fold and peak in intensity 1–2 weeks after the completion of the radiation treatment course 29–31…”

Section: Presentation and Timingmentioning

confidence: 99%

“…The RISRAS noted above also incorporates a patient component which focus on skin tenderness, itchiness, burning, and functional activity 43. Six-point Likert scales quantifying symptoms are also in use 31. Other quality of life assessments also exist, such as the EORTC breast cancer-specific quality of life questionnaire (QLQ-BR-23) and the Functional Assessment of Cancer Therapy-Breast (FACT-B) 46,47.…”

Section: Assessment and Scoringmentioning

confidence: 99%

“…Patient-reported symptoms were also not significantly different between the three arms. Multiple studies have shown that the use of aloe vera gel is ineffective in reducing both physician and patient-reported acute skin reactions when compared with placebo or no treatment 31,69. In one study, patients actually had worse breast pain and dry desquamation when using aloe vera 70.…”

Section: Evidence For Radiation Dermatitis Preventionmentioning

confidence: 99%

See 2 more Smart Citations

Acute radiation dermatitis in breast cancer patients: challenges and solutions

Kole¹,

Kole²,

Moran³

2017

BCTT

102

106

View full text Add to dashboard Cite

Nearly all women who receive radiotherapy (RT) for breast cancer experience some degree of radiation dermatitis. However, evidence describing the appropriate management of radiation dermatitis is often lacking or contradictory. Here, we summarize the available literature regarding radiation dermatitis causes, the presentation and timing of symptoms, methods for dermatitis assessment and prevention, and review evidence-based management strategies.

show abstract

Section: Presentation and Timingmentioning

confidence: 99%

Section: Assessment and Scoringmentioning

confidence: 99%

Section: Evidence For Radiation Dermatitis Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Acute radiation dermatitis in breast cancer patients: challenges and solutions

Kole¹,

Kole²,

Moran³

2017

BCTT

102

106

View full text Add to dashboard Cite

show abstract

“…The most recent systematic reviews highlight that there is no enough evidence about interventions for the prevention and treatment of radiodermatitis in subjects receiving radiotherapy, although the positive effects of hyaluronic acid had been confirmed by another systematic review with other types of lesions . Other treatments, such as Aloe vera , trolamine, sucralfate, and other formulations of hyaluronic acid did not prove to be effective in the treatment of radiodermatitis, and some studies even found that they were counterproductive …”

Section: Discussionmentioning

confidence: 99%

“…In severe radiodermatitis, corticosteroids have been found to play a role in reducing complications, even though they did not reduce the number of events nor the level of seriousness . Other treatments, such as Aloe vera , trolamine, sucralfate, and other hyaluronic acid formulations have not proved to be effective in treating radiodermatitis, and in some cases, they have even been counterproductive …”

Section: Introductionmentioning

confidence: 99%

Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review

Presta

Puliatti

Bonetti

et al. 2019

International Wound Journal

View full text Add to dashboard Cite

One of the principal side effects in patients that receive radiotherapy is radiodermatitis. Radiodermatitis can be highly invalidating for patients, causing pain, ulceration, swelling, and increased infection risk, with a negative effect on the quality of life, requiring dressings and medications. Therapeutic approaches reported so far in the literature have not proved to be effective in treating radiodermatitis. Therefore, new approaches are needed to deal with these side effects more effectively. The aim of the study was to evaluate the effectiveness of hyaluronic acid gel (HAG) (Jalosome soothing gel) for the treatment of a case of radiodermatitis. This is a case study of a patient affected by squamous cell carcinoma at the tongue base, who was treated with head and neck radiotherapy associated with the administration of cetuximab. About 1 month after this therapy was started the patient developed radiodermatitis, which did not regress with standard treatment. Therefore, HAG was applied once a day for about 20 days. The regression of radiodermatitis was measured using the Radiation Toxicity/Oncology Grading scale, pain relief was measured with a numerical scale, and patient satisfaction was done through a semi‐structured interview. The patient presented a dramatic reduction of skin toxicity, which had been resistant to all previous therapeutic approaches. Pain, which was severe at the beginning, gradually disappeared. The patient showed great satisfaction for the reduction of pain and the regression of the radiodermatitis. The effectiveness of HAG appears to be promising for the treatment of radiodermatitis.

show abstract

Chinese clinical practice guidelines for the prevention and treatment of radiation‐induced dermatitis

Fan,

Feng,

Yuan

2023

Precision Radiation Oncology

View full text Add to dashboard Cite

Radiation‐induced dermatitis is one of the most prevalent complications in patients undergoing cancer radiotherapy and poses a significant challenge to cancer therapy. The symptoms include erythema, dry desquamation, and moist desquamation, which are frequently observed in patients with breast, head and neck, anal, and vulvar cancers. Early skin reactions typically manifest within 2–4 weeks following the initiation of radiotherapy. In severe cases, acute dermatitis can cause radiotherapy interruptions, prolong treatment time, and ultimately affect patient outcomes and quality of life. Currently, there are numerous guidelines on radiation dermatitis, including the Multinational Association of Supportive Care in Cancer (MASCC), British Columbia Cancer Agency (BCCA), Oncology Nursing Society (ONS), and UK Society of Radiographers (SCoR) guidelines. In China, dermatology experts have drafted a consensus. However, due to the differing backgrounds of experts, recommendations among guidelines vary. These guidelines were first developed by Chinese radiation oncologists. The evidence‐based guideline in this paper fully considers and adopts China's national conditions; hence, it can be easily applied in daily practice.

show abstract

Three-Arm Randomized Phase III Trial: Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy

Cited by 62 publications

References 30 publications

Acute radiation dermatitis in breast cancer patients: challenges and solutions

Acute radiation dermatitis in breast cancer patients: challenges and solutions

Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review

Chinese clinical practice guidelines for the prevention and treatment of radiation‐induced dermatitis

Contact Info

Product

Resources

About